Mays Oncology Intelligence
48+ Therapeutic Programs

Oncology Portfolio

Comprehensive view of the Mays Cancer Center therapeutic portfolio, from home-grown PROTAC degraders to industry-sponsored trials.

Optimize Portfolio

48+

Molecules

5

Tiers

20+

Clinical Trials

$50M+

Total Funding

Tiering Methodology

How we classify the Mays Cancer Center oncology portfolio

1
Home-Grown Therapeutics

Invented at UT Health SA CIDD/IDD. IP-generating molecules with the highest strategic value.

11molecules
2
Investigator-Initiated Trials

IIT trials conceived and run by Mays Cancer Center faculty. Clinical innovation driven by institutional expertise.

10molecules
3
Commercial Deployment

FDA-approved drugs actively administered at Mays Cancer Center as standard of care.

1molecules
4
FDA-Approved Legacy

Drugs whose clinical development ran through Mays, now FDA-approved.

5molecules
5
Industry-Sponsored

Mays Cancer Center serves as a clinical trial site for industry-sponsored studies.

0molecules

Portfolio Lifecycle

Where each featured molecule sits in the 12-stage pharma lifecycle

Featured Molecules - Lifecycle Position

Pipeline Overview

All molecules grouped by modality across development stages

Pipeline Swim Lanes by Modality

1

Home-Grown Therapeutics

Invented at UT Health SA CIDD/IDD with the highest institutional strategic value

DT2216
PROTACTarget: BCL-XL

Phase

1/2

PI: Dr. Daruka Mahadevan

NCI R01 + CPRIT
Explore DT2216 →
186RNL (Rhenium Obisbemeda)
NanoliposomeTarget: GBM tumors

Phase

1/2

PI: Dr. Andrew Brenner

FDA Fast Track + Orphan Drug + RMAT
Explore 186RNL →
Amuvatinib (MP-470)
Small MoleculeTarget: c-Kit/c-Met/PDGFR

Phase

1/2 (completed)

PI: Dr. Daruka Mahadevan

NCI + CPRIT
Explore Amuvatinib →
753B (BCL-xL/BCL-2 Dual PROTAC)
PROTACTarget: BCL-xL/BCL-2

Stage

Preclinical

PI: Dr. Daohong Zhou

DT-MCL1 (MCL-1 PROTAC)
PROTACTarget: MCL-1

Stage

Lead Optimization

PI: CIDD

DT-KRAS (KRAS G12D Degrader)
PROTACTarget: KRAS G12D

Stage

Hit-to-Lead

PI: CIDD

SF2523 (PI3K+BRD4 Dual Inhibitor)
Small MoleculeTarget: PI3K/BRD4

Stage

IND-Enabling

PI: Dr. Daruka Mahadevan

SRX3177 (PI3K+BRD4+CDK4/6 Triple Inhibitor)
Small MoleculeTarget: PI3K/BRD4/CDK4/6

Stage

IND-Enabling

PI: Dr. Daruka Mahadevan

CIDD-0149897 (ER-beta Agonist)
Small MoleculeTarget: ER-beta

Stage

Preclinical

NCI $5M

PI: Dr. Stanton McHardy

CIDD99 (Capsazepine-derived)
Small MoleculeTarget: Anticancer

Stage

Preclinical

NIH STTR

PI: Dr. Gonzales/Dr. McHardy

MBD6-targeted (TET2-mutant Myeloid)
PlatformTarget: MBD6/TET2

Stage

Discovery

CPRIT $900K

PI: Dr. Xu

2

Investigator-Initiated Trials

IIT trials conceived and run by Mays Cancer Center faculty

Sacituzumab Govitecan (GBM)
ADCTarget: Trop-2

Phase

2

PI: Dr. William Kelly

Explore SG-GBM →
BSI-082
mAbTarget: SIRPα

Phase

1

PI: Dr. John Sarantopoulos

Explore BSI-082 →
Imipramine + Lomustine
Small MoleculeTarget: GBM

Phase

2

NCT04863950
Avasopasem (GC4419)
Small MoleculeTarget: SOD mimetic

Phase

1

NCT07137871
CPRIT $3.2M
eRapa (Encapsulated Rapamycin)
Small MoleculeTarget: mTOR

Phase

2

NCT04375813
Loncastuximab + Roflumilast + R-CHOP
ADCTarget: CD19

Phase

1b

NCT06977711
Tislelizumab + SX-682
mAbTarget: PD-1/CXCR1/2

Phase

2

NCT05604560
Tremelimumab + Durvalumab (HCC)
mAbTarget: CTLA-4/PD-L1

Phase

2

NCT06526104
Zanzalintinib + Durvalumab + Tremelimumab (HCC)
Small MoleculeTarget: c-MET/VEGFR/CTLA-4/PD-L1

Phase

2

EGCG (Epigallocatechin Gallate)
Small MoleculeTarget: Colon cancer prevention

Phase

Early Phase 1

NCT02891538
3

Commercial Deployment

FDA-approved drugs actively administered at Mays Cancer Center

Pluvicto (177Lu-PSMA-617)

Only civilian center in South Texas

RLTTarget: PSMAPartner: Novartis

Commercial

Status

Explore Pluvicto →
4

FDA-Approved Legacy

Drugs whose clinical development ran through Mays, now FDA-approved

FDA 2022

Pacritinib (Vonjo)

Small MoleculeJAK2/FLT3
FDA 2021

Besremi (Ropeginterferon)

PEG-InterferonInterferon-alpha
FDA 2019

Fedratinib (Inrebic)

Small MoleculeJAK2
FDA 2023

Momelotinib (Ojjaara)

Small MoleculeJAK1/JAK2/ACVR1
FDA 2023

Elacestrant (Orserdu)

Oral SERDER
5

Industry-Sponsored Trials

Mays Cancer Center as a clinical trial site for 20 industry-sponsored studies

NameSponsorPhaseIndicationNCT #Status
Pembrolizumab (Keytruda)MerckPhase 3Various solid tumorsNCT02362594Active
Nivolumab (Opdivo)Bristol-Myers SquibbPhase 3Renal cell carcinomaNCT03793166Active
Atezolizumab (Tecentriq)Genentech/RochePhase 3NSCLCNCT04091490Active
Trastuzumab Deruxtecan (Enhertu)Daiichi Sankyo/AstraZenecaPhase 3HER2+ breast cancerNCT04784715Recruiting
Sacituzumab Govitecan (Trodelvy)Gilead SciencesPhase 3mTNBCNCT04595565Active
Olaparib (Lynparza)AstraZenecaPhase 3Ovarian cancer (BRCA+)NCT03737643Active
Rucaparib (Rubraca)Clovis OncologyPhase 2Prostate cancer (BRCA+)NCT03533946Active
Sotorasib (Lumakras)AmgenPhase 3KRAS G12C NSCLCNCT04303780Active
Adagrasib (Krazati)Mirati TherapeuticsPhase 2KRAS G12C solid tumorsNCT04685135Recruiting
Enfortumab Vedotin (Padcev)Astellas/SeagenPhase 3Urothelial carcinomaNCT04223856Active
Zanubrutinib (Brukinsa)BeiGenePhase 3CLL/SLLNCT04116437Recruiting
Pirtobrutinib (Jaypirca)Eli LillyPhase 3MCLNCT04965493Active
Belzutifan (Welireg)MerckPhase 3RCC (VHL-driven)NCT04586231Active
Mirvetuximab Soravtansine (Elahere)ImmunoGenPhase 3FRα+ ovarian cancerNCT04209855Active
Dato-DXd (Datopotamab)Daiichi Sankyo/AstraZenecaPhase 3NSCLC / TNBCNCT05104866Recruiting
Tarlatamab (Imdelltra)AmgenPhase 2Small cell lung cancerNCT05060016Active
InavolisibGenentech/RochePhase 3HR+/HER2- breast cancer (PIK3CA)NCT04191382Active
Capivasertib (Truqap)AstraZenecaPhase 3HR+/HER2- breast cancerNCT04305496Active
Ciltacabtagene Autoleucel (Carvykti)J&J/Legend BiotechPhase 3Multiple myelomaNCT05257083Recruiting
Teclistamab (Tecvayli)JanssenPhase 3Multiple myeloma (BCMA)NCT05083169Active

Funding Overview

Estimated funding allocation across the oncology portfolio ($ millions)

Portfolio Funding Sources

Publication Timeline

Portfolio-related publications by year

Annual Publication Output